General
Preferred name
dolasetron
Synonyms
Dolasetron Mesylate hydrate ()
Dalasetron Mesylate Hydrate ()
Dolasetron mesylate ()
Anzemet hydrate,MDL-73147EF ()
Dolasetron mesylate monohydrate ()
Dolasetron mesilate ()
MDL-73147EF ()
Dolasetron mesylate anhydrous ()
Dolasetron methanesulfonate ()
MDL 73,147EF ()
Anzemet ()
Dolasetron mesilate monohydrate ()
P&D ID
PD016336
CAS
878143-33-0
115956-13-3
Tags
natural product
drug
available
Drug Status
investigational
approved
withdrawn
Max Phase
Phase 4
Drug indication
Anti-Emetic
Antimigraine
First approval
1997
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
7
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
29
Properties
(calculated by RDKit )
Molecular Weight
324.15
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
6
Aromatic Ring Count
2
cLogP
2.52
TPSA
62.4
Fraction CSP3
0.47
Chiral centers
5.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Neuroscience
Target
5-HT3
5-HT Receptor
MOA
5-HT Receptor antagonist
ATC
A04AA04
Toxicity type
cardiovascular
Source data
